Vanguard Personalized Indexing Management LLC Has $17.14 Million Position in Vertex Pharmaceuticals Incorporated $VRTX

Vanguard Personalized Indexing Management LLC increased its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 7.6% during the second quarter, Holdings Channel reports. The institutional investor owned 38,491 shares of the pharmaceutical company’s stock after purchasing an additional 2,729 shares during the quarter. Vanguard Personalized Indexing Management LLC’s holdings in Vertex Pharmaceuticals were worth $17,138,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in VRTX. Price T Rowe Associates Inc. MD grew its position in Vertex Pharmaceuticals by 72.5% during the first quarter. Price T Rowe Associates Inc. MD now owns 2,917,227 shares of the pharmaceutical company’s stock worth $1,414,331,000 after buying an additional 1,226,527 shares in the last quarter. Nuveen LLC acquired a new stake in Vertex Pharmaceuticals during the first quarter worth about $484,053,000. Jennison Associates LLC grew its position in Vertex Pharmaceuticals by 17.2% during the first quarter. Jennison Associates LLC now owns 5,062,442 shares of the pharmaceutical company’s stock worth $2,454,373,000 after buying an additional 744,680 shares in the last quarter. Goldman Sachs Group Inc. grew its position in Vertex Pharmaceuticals by 28.9% during the first quarter. Goldman Sachs Group Inc. now owns 1,775,194 shares of the pharmaceutical company’s stock worth $860,650,000 after buying an additional 398,460 shares in the last quarter. Finally, Alyeska Investment Group L.P. grew its position in Vertex Pharmaceuticals by 456.9% during the first quarter. Alyeska Investment Group L.P. now owns 431,804 shares of the pharmaceutical company’s stock worth $209,347,000 after buying an additional 354,269 shares in the last quarter. 90.96% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, Director Bruce I. Sachs bought 5,000 shares of the business’s stock in a transaction dated Wednesday, August 6th. The stock was bought at an average price of $389.68 per share, for a total transaction of $1,948,400.00. Following the completion of the purchase, the director owned 45,000 shares of the company’s stock, valued at approximately $17,535,600. The trade was a 12.50% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 0.20% of the company’s stock.

Vertex Pharmaceuticals Trading Down 1.7%

NASDAQ:VRTX opened at $407.79 on Friday. Vertex Pharmaceuticals Incorporated has a 1 year low of $362.50 and a 1 year high of $519.88. The firm has a 50 day moving average of $393.91 and a 200-day moving average of $439.18. The stock has a market capitalization of $104.55 billion, a P/E ratio of 29.15 and a beta of 0.43.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its earnings results on Monday, August 4th. The pharmaceutical company reported $4.52 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.24 by $0.28. Vertex Pharmaceuticals had a net margin of 31.86% and a return on equity of 23.91%. The company had revenue of $2.94 billion during the quarter, compared to analysts’ expectations of $2.90 billion. During the same quarter in the previous year, the company posted ($12.83) earnings per share. Vertex Pharmaceuticals’s quarterly revenue was up 11.3% compared to the same quarter last year. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, analysts forecast that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on VRTX shares. UBS Group set a $553.00 target price on Vertex Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, August 5th. Guggenheim cut their price target on shares of Vertex Pharmaceuticals from $558.00 to $546.00 and set a “buy” rating for the company in a research note on Wednesday, August 6th. Morgan Stanley cut their price target on shares of Vertex Pharmaceuticals from $439.00 to $438.00 and set an “equal weight” rating for the company in a research note on Friday. Truist Financial set a $490.00 price target on shares of Vertex Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, August 5th. Finally, Cantor Fitzgerald cut their price target on shares of Vertex Pharmaceuticals from $535.00 to $485.00 and set an “overweight” rating for the company in a research note on Tuesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and twelve have given a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $494.38.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.